These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 26514352)

  • 1. Rationale and design of the ODIn-AF Trial: randomized evaluation of the prevention of silent cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation.
    Schrickel JW; Linhart M; Bänsch D; Thomas D; Nickenig G
    Clin Res Cardiol; 2016 Feb; 105(2):95-105. PubMed ID: 26514352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
    Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical comparative study regarding interrupted and uninterrupted dabigatran therapy during perioperative periods of cryoballoon ablation for paroxysmal atrial fibrillation.
    Nakamura R; Okishige K; Shigeta T; Nishimura T; Kurabayashi M; Yamauchi Y; Sasano T; Hirao K
    J Cardiol; 2019 Aug; 74(2):150-155. PubMed ID: 31029455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymptomatic cerebral lesions during pulmonary vein isolation under uninterrupted oral anticoagulation.
    Martinek M; Sigmund E; Lemes C; Derndorfer M; Aichinger J; Winter S; Jauker W; Gschwendtner M; Nesser HJ; Pürerfellner H
    Europace; 2013 Mar; 15(3):325-31. PubMed ID: 23097222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of cerebral thromboembolic events during long-term follow-up in patients treated with transcatheter ablation for atrial fibrillation.
    Gaita F; Sardi D; Battaglia A; Gallo C; Toso E; Michielon A; Caponi D; Garberoglio L; Castagno D; Scaglione M
    Europace; 2014 Jul; 16(7):980-6. PubMed ID: 24446510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
    Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
    Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postablation cerebral embolisms in balloon-based atrial fibrillation ablation with periprocedural direct oral anticoagulants: A comparison between cryoballoon and HotBalloon ablation.
    Nakamura K; Sasaki T; Take Y; Okazaki Y; Inoue M; Motoda H; Miki Y; Niijima K; Yamashita E; Koyama K; Funabashi N; Naito S
    J Cardiovasc Electrophysiol; 2019 Jan; 30(1):39-46. PubMed ID: 30288849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and predictors of silent cerebral thromboembolic lesions after catheter ablation for atrial fibrillation in patients treated with direct oral anticoagulants.
    Doi A; Takagi M; Kakihara J; Hayashi Y; Tatsumi H; Fujimoto K; Sugioka K; Yoshiyama M
    Heart Vessels; 2017 Oct; 32(10):1227-1235. PubMed ID: 28466408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation.
    Eitel C; Koch J; Sommer P; John S; Kircher S; Bollmann A; Arya A; Piorkowski C; Hindricks G
    Europace; 2013 Nov; 15(11):1587-93. PubMed ID: 23703362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation.
    Hansen PS; Sanchez R; Walfridsson H
    Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose dabigatran versus uninterrupted acenocoumarol for peri-procedural anticoagulation in atrial fibrillation catheter ablation.
    Efremidis M; Vlachos K; Letsas KP; Giannopoulos G; Lioni L; Georgopoulos S; Vadiaka M; Deftereos S; Sideris A
    J Electrocardiol; 2015; 48(5):840-4. PubMed ID: 26152604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation use and clinical outcomes after catheter ablation in patients with persistent and longstanding persistent atrial fibrillation.
    Liang JJ; Elafros MA; Mullen MT; Muser D; Hayashi T; Enriquez A; Pathak RK; Zado ES; Santangeli P; Arkles JS; Schaller RD; Supple GE; Frankel DS; Garcia FC; Deo R; Lin D; Riley MP; Nazarian S; Dixit S; Marchlinski FE; Callans DJ
    J Cardiovasc Electrophysiol; 2018 Jun; 29(6):823-832. PubMed ID: 29513397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The Use of Dabigatran for Prevention of Thromboembolic Complications in Patients Underwent Atrial Fibrillation Catheter Ablation].
    Mamchur SE; Gorbunova EV; Sherbinina DA; Romanova MP
    Kardiologiia; 2015; 55(4):30-5. PubMed ID: 26502500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low rate of asymptomatic cerebral embolism and improved procedural efficiency with the novel pulmonary vein ablation catheter GOLD: results of the PRECISION GOLD trial.
    De Greef Y; Dekker L; Boersma L; Murray S; Wieczorek M; Spitzer SG; Davidson N; Furniss S; Hocini M; Geller JC; Csanádi Z;
    Europace; 2016 May; 18(5):687-95. PubMed ID: 26826134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation.
    Zhao Y; Lu Y; Qin Y
    Int J Cardiol; 2018 Nov; 270():167-171. PubMed ID: 29903520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients.
    Koektuerk B; Turan CH; Yorgun H; Keskin K; Schoett M; Dahmen A; Gorr E; Yang A; Hoppe C; Horlitz M; Turan RG
    Cardiovasc Ther; 2016 Jun; 34(3):144-51. PubMed ID: 26880220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature.
    Hohnloser SH; Camm AJ
    Europace; 2013 Oct; 15(10):1407-11. PubMed ID: 23954917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboembolic and bleeding risks in patients undergoing atrial fibrillation ablation: oral anticoagulation perspectives.
    Briceño DF; Madan N; Romero J; Londoño A; Villablanca PA; Natale A; Di Biase L
    Expert Opin Drug Saf; 2017 Jul; 16(7):769-777. PubMed ID: 28475380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it safe to stop oral anticoagulation after catheter ablation for atrial fibrillation?
    Romero J; Avendano R; Diaz JC; Taveras J; Lupercio F; Di Biase L
    Expert Rev Cardiovasc Ther; 2019 Jan; 17(1):31-41. PubMed ID: 30460874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.